Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clyde Bailey

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
Blood Cancer Journal|October 16, 2025
Equal survival for Black Americans with multiple myeloma when appropriately matched to White AmericansDavid E Mery, Guido Tricot, Samer Al Hadidi, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Blood Cancer Journal|February 14, 2024
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systemsWancheng Guo, Yihao Zhan, David Mery, et al.
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Cancers|August 27, 2021
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple MyelomaLakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, et al.
Cancer Biomarkers : Section a of Disease Markers|June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myelomaFumou Sun, Yan Cheng, Catherine Ma, et al.
Blood Cancer Journal|October 16, 2025
Equal survival for Black Americans with multiple myeloma when appropriately matched to White AmericansDavid E Mery, Guido Tricot, Samer Al Hadidi, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Blood Cancer Journal|February 14, 2024
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systemsWancheng Guo, Yihao Zhan, David Mery, et al.
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Pageof 3